287 related articles for article (PubMed ID: 8595511)
1. Rationale and experience with reverse transcriptase inhibitors and protease inhibitors.
Vella S
J Acquir Immune Defic Syndr Hum Retrovirol; 1995; 10 Suppl 1():S58-61. PubMed ID: 8595511
[TBL] [Abstract][Full Text] [Related]
2. Long-term analysis of the resistance development in HIV-1 positive patients treated with protease and reverse transcriptase inhibitors: correlation of the genotype and disease progression.
Václavíková J; Weber J; Machala L; Reinis M; Linka M; Brůcková M; Vandasová J; Stanková M; Konvalinka J
Acta Virol; 2005; 49(1):29-36. PubMed ID: 15929396
[TBL] [Abstract][Full Text] [Related]
3. Highly active antiretroviral therapy failure and protease and reverse transcriptase human immunodeficiency virus type 1 gene mutations.
Monno L; Appice A; Cavaliere R; Scarabaggio T; Angarano G
J Infect Dis; 1999 Aug; 180(2):568-71. PubMed ID: 10395885
[No Abstract] [Full Text] [Related]
4. Cross-resistance within the protease inhibitor class.
Race E
Antivir Ther; 2001; 6 Suppl 2():29-36. PubMed ID: 11678476
[No Abstract] [Full Text] [Related]
5. Practical issues regarding the use of antiretroviral therapy for HIV infection.
Deeks SG
West J Med; 1998 Feb; 168(2):133-9. PubMed ID: 9499754
[TBL] [Abstract][Full Text] [Related]
6. Antiretroviral therapies.
Owen WF
Clin Podiatr Med Surg; 1998 Apr; 15(2):227-39. PubMed ID: 9576051
[TBL] [Abstract][Full Text] [Related]
7. HIV treatment options.
Smith D
AIDS Treat News; 1998 May; (No 294):4-5. PubMed ID: 11365404
[TBL] [Abstract][Full Text] [Related]
8. Structural and biochemical effects of human immunodeficiency virus mutants resistant to non-nucleoside reverse transcriptase inhibitors.
Domaoal RA; Demeter LM
Int J Biochem Cell Biol; 2004 Sep; 36(9):1735-51. PubMed ID: 15183341
[TBL] [Abstract][Full Text] [Related]
9. Antiretroviral resistance mutations in human immunodeficiency virus type 1 reverse transcriptase and protease from paired cerebrospinal fluid and plasma samples.
Venturi G; Catucci M; Romano L; Corsi P; Leoncini F; Valensin PE; Zazzi M
J Infect Dis; 2000 Feb; 181(2):740-5. PubMed ID: 10669367
[TBL] [Abstract][Full Text] [Related]
10. HIV-1 reverse transcriptase inhibitor resistance mutations and fitness: a view from the clinic and ex vivo.
Martinez-Picado J; Martínez MA
Virus Res; 2008 Jun; 134(1-2):104-23. PubMed ID: 18289713
[TBL] [Abstract][Full Text] [Related]
11. [AIDS; new developments. II. Treatment of HIV infection].
Borleffs JC; Esseveld F; Hoepelman IM; Boucher CA
Ned Tijdschr Geneeskd; 1997 May; 141(21):1036-43. PubMed ID: 9340560
[TBL] [Abstract][Full Text] [Related]
12. Absence of resistance mutations in antiretroviral-naive patients treated with ritonavir-boosted saquinavir.
Ananworanich J; Hirschel B; Sirivichayakul S; Ubolyam S; Jupimai T; Prasithsirikul W; Chetchotisakd P; Kiertiburanakul S; Munsakul W; Raksakulkarn P; Tansuphasawadikul S; Schutz M; Snowden W; Ruxrungtham K;
Antivir Ther; 2006; 11(5):631-5. PubMed ID: 16964832
[TBL] [Abstract][Full Text] [Related]
13. Rapid detection of drug resistant HIV -1 to reverse transcriptase and protease inhibitors in HIV-infected patients receiving highly active antiretroviral therapies.
Yu M; Kabat W; Wang J
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2000 Dec; 14(4):325-9. PubMed ID: 11471017
[TBL] [Abstract][Full Text] [Related]
14. Protease inhibitors and prevention of cross resistance.
Levin J
AIDS Treat News; 1995 Oct; (no 232):1-3. PubMed ID: 11362875
[TBL] [Abstract][Full Text] [Related]
15. Is there a role for non-nucleoside reverse transcriptase inhibitors in the treatment of HIV infection?
Kilby JM; Saag MS
Infect Agents Dis; 1994 Dec; 3(6):313-23. PubMed ID: 7534192
[TBL] [Abstract][Full Text] [Related]
16. Drug resistance genotypes predict response to amprenavir-containing regimens in highly drug-experienced HIV-1-infected patients.
Sabin CA; Wilkins E; Murphy M; Fisher M; de Ruiter A; Easterbrook PJ; Leen C; Vlahakis E; Cane PA; Li X; Pillay D;
Antivir Ther; 2003 Aug; 8(4):301-8. PubMed ID: 14518699
[TBL] [Abstract][Full Text] [Related]
17. Viral resistance and the selection of antiretroviral combinations.
Larder BA
J Acquir Immune Defic Syndr Hum Retrovirol; 1995; 10 Suppl 1():S28-33. PubMed ID: 8595505
[TBL] [Abstract][Full Text] [Related]
18. No tease this time--pros and cons of a long-awaited anti-HIV drug.
Chang HE
Posit Aware; 1996; 7(1):18-20. PubMed ID: 11363118
[TBL] [Abstract][Full Text] [Related]
19. Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.
Prescrire Int; 2004 Aug; 13(72):144-50. PubMed ID: 15532140
[TBL] [Abstract][Full Text] [Related]
20. HIV resistance: the new enemy.
Colvin R
Common Factor; 1997 Nov; (No 11):6-7. PubMed ID: 11364845
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
